Erschienen in:
01.01.2020 | Skin Cancer (T Ito, Section Editor)
Epidermal Growth Factor Receptor’s Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies
verfasst von:
Priscila Oliveira de Lima, Shannon Joseph, Benedict Panizza, Fiona Simpson
Erschienen in:
Current Treatment Options in Oncology
|
Ausgabe 1/2020
Einloggen, um Zugang zu erhalten
Opinion statement
Recent studies have evidenced the potential of combining anti-EGFR therapies with anti-PD-1/PD-L1 checkpoint therapies. Both anti-EGFR and anti-PD-1/PD-L1 have been separately tested in the treatment of cutaneous SCC (cSCC). Here, we review recent data on EGFR in the context of cancer progression, as a prognostic and as a therapeutic target in cSCC. Anti-EGFR/checkpoint immunotherapy and other combination therapy approaches are discussed. With the advent of immunotherapy, EGFR is still a valid cSCC target.